The dose makes the poison: next generation AAV vectors can save the day

Cell & Gene Therapy Insights 2021; 7(6), 717–722


Published: 13 July 2021
Julia Fakhiri, Jihad El Andari

Julia Fakhiri obtained her PhD in Biology from the University of Heidelberg (Germany), where she worked on different aspects of gene therapy, from parvovirus capsid engineering to in vivo applications of AAV-CRISPR/Cas9. In her postdoctoral training at the Department of Infectious Diseases of the University Hospital Heidelberg, she also worked on in vivo screening of AAV libraries in collaboration with industry partners. Dr. Fakhiri is currently a postdoctoral fellow at Roche Pharma Research and Early Development (pRED), Roche Diagnostics in Penzberg, Germany. Her research mainly focuses on the development of processes for production of recombinant viral vectors.

Jihad (josef) El Andari is currently a senior postdoctoral fellow in the laboratory of Dirk Grimm at the medical faculty and BioQuant center at the University of Heidelberg (Germany). His research primarily emphasizes on developing novel synthetic vectors with enhanced properties to target the musculature and the central nervous system. Dr. El Andari has obtained his Ph.D. in Molecular Microbiology from the University of Freiburg (Germany) that was followed by a postdoctoral stint at the Center of Synthetic Microbiology (SYNMIKRO) at the University of Marburg (Germany).